Symbols

SPRO

Spero Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 1

EPS Beats Expectation

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About SPRO

Spero Therapeutics, Inc.

A multi-asset, clinical-stage biopharmaceutical company focused on novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases

Industry

Pharmaceutical

Established Date

Listing Date

11/02/2017

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.sperotherapeutics.com

Security Type

Common stock

Office address

675 Massachusetts Avenue 14th Floor Cambridge Massachusetts 02139

Business

Introduction

Spero Therapeutics, Inc., was incorporated in December 2013 under the laws of the State of Delaware. The company is a clinical-stage biopharmaceutical company focused on identifying and developing new therapies for rare diseases and diseases with high unmet need. The company's clinical stage product candidate teipenem HBr has completed its second Phase 3 trial and has the potential to be the first oral carbapenem for the treatment of adult patients with complex urinary tract infections caused by certain microorganisms, including pyelonephritis.

Company Financials

EPS

SPRO has released its 2025 Q4 earnings. EPS was reported at 0.53, versus the expected -0.2, beating expectations. The chart below visualizes how SPRO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

SPRO has released its 2025 Q4 earnings report, with revenue of 41.30M, reflecting a YoY change of 174.51%, and net profit of 31.52M, showing a YoY change of 250.90%. The Sankey diagram below clearly presents SPRO's revenue sources and cost distribution.